|
TOP 5 INSIGHTS IN CLINICAL SUPPLY CHAIN & LOGISTICS
JANUARY EDITION
|
|
|
|
|
|
Emerging cell and gene therapy teams don’t fail at clinical supply because they lack systems—they struggle because alignment, ownership, and demand signals aren’t clearly defined. Learn how small clinical-stage teams can use disciplined S&OP practices to align clinical demand with supply, reduce risk, and keep trials on track.
|
|
|
|
|
|
As clinical trials grow more global, complex, and decentralized, lean biotech teams are being stretched by supply models built for scale, not agility. Discover how flexible, integrated clinical supply strategies can reduce handoffs, protect material integrity, and help emerging sponsors keep trials moving with confidence.
|
|
|
|
|
|
Too often, clinical supply is brought in to fix problems that could have been prevented with early planning, turning a strategic function into a last-minute scramble that puts FPFV, timelines, and budgets at risk. See why embedding clinical supply from the start is the difference between controlled execution and constant crisis.
|
|
|
|
|
|
A biotech developing complex T-cell therapies gained real-time, audit-ready visibility across its global clinical supply chain by integrating Signant Health’s GxP Inventory solution. Explore how centralized inventory oversight and automated controls can reduce risk, improve efficiency, and support smoother trial execution.
|
|
|
|
|
|
Emerging markets hold massive potential for global clinical trials, but fragile supply chains remain the biggest barrier to reliability, compliance, and patient access. Learn how clinical supply leaders can redesign supply chains for high-variability regions and turn emerging markets into dependable pathways for global development.
|
|
|
|
|
|
|
